Biohaven shares rose 32.60% after the US Food and Drug Administration accepted the company's reapplication for brain disease drugs.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.